Tags : Enspryng

Biotech Clinical Trials

Genentech to Present New Data of Enspryng (satralizumab-mwge) for Neuromyelitis

Shots: Genentech reports the new data for Enspryng on reducing relapse severity in the treatment of neuromyelitis optical spectrum disorder (NMOSD), to be presented at MSVirtual2020. In a pos-thoc analysis, 79% reduction in relapse severity by vs PBO (19% vs 35%) in P-III SAkura studies. Pooled data from Sakura OLE studies support the continued effect […]Read More